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We examine the effects of two important types of medical innovation—diagnostic imaging innovation
and pharmaceutical innovation—and cancer incidence rates on U.S. cancer mortality rates during the
period 1996-2006.  The outcome measure we use is not subject to lead-time bias, and our measures
of medical innovation are based on extensive data on treatments given to large numbers of patients
with different types of cancer.  
We estimate difference-in-difference models of the age-adjusted cancer mortality rate using longitudinal,
annual, cancer-site-level data on over 60 cancer sites.  There is a significant inverse relationship between
the cancer mortality rate and both lagged imaging innovation and contemporaneous drug innovation,
and a significant positive relationship between the cancer mortality rate and the lagged incidence rate.
Imaging innovation, drug innovation, and declining incidence jointly explain about three-fourths of
the decline in cancer mortality. 
Only 7% of the mortality decline is attributable to the decline in (lagged) incidence.  About one-fourth
of the mortality decline is attributable to drug innovation, and 40% of the decline is attributable to
(lagged) imaging innovation.  Life expectancy at birth may have been increased by almost three months









The war on cancer began with the National Cancer Act of 1971. The act was 
intended "to amend the Public Health Service Act so as to strengthen the National Cancer 
Institute in order to more effectively carry out the national effort against cancer.”   
Two types of statistics are often used to assess progress in the war on cancer: 
survival rates and mortality rates.  Survival rates are typically expressed as the proportion 
of patients alive at some point subsequent to the diagnosis of their cancer.  For example, 
the observed 5-year survival rate is defined as follows:  
 
5-year Survival Rate = Number of people diagnosed with cancer at time t alive at 
time t+5 / Number of people diagnosed with cancer at time t 
= 1 – (Number of people diagnosed with cancer at time t dead at time t+5 / 
Number of people diagnosed with cancer at time t) 
 
Hence, the survival rate is based on a conditional (upon previous diagnosis) 
mortality rate.  The second type of statistic is the unconditional cancer mortality rate: the 
number of deaths, with cancer as the underlying cause of death, occurring during a year 
per 100,000 population.  
As shown in Figure 1a, the 5-year relative survival rate from cancer has increased 
steadily since the mid 1970s.
1  Although this increase suggests that there has been 
significant progress in the war against cancer, it might simply be a reflection of 
(increasing) lead-time bias.  Lead time bias is the bias that occurs when two tests for a 
disease are compared, and one test (the new, experimental one) diagnoses the disease 
earlier, but there is no effect on the outcome of the disease--it may appear that the test 
prolonged survival, when in fact it only resulted in earlier diagnosis when compared to 
traditional methods.
2  Welch et al (2000) argued that “while 5-year survival is a perfectly 
valid measure to compare cancer therapies in a randomized trial, comparisons of 5-year 
survival rates across time (or place) may be extremely misleading. If cancer patients in 
the past always had palpable tumors at the time of diagnosis while current cancer patients 
                                                 
1 Relative survival is defined as the ratio of the proportion of observed survivors (all causes of death) in a 
cohort of cancer patients to the proportion of expected survivors in a comparable cohort of cancer-free 
individuals. The formulation is based on the assumption of independent competing causes of death. Since a 
cohort of cancer-free individuals is difficult to obtain, expected life tables are used, i.e. it is assumed that 
cancer deaths are a negligible proportion of all deaths.  Ederer et al (1961). 
2 See American College of Physicians (1999).   2
include those diagnosed with microscopic abnormalities, then 5-year survival would be 
expected to increase over time even if new screening and treatment strategies are 
ineffective.”  Welch et al (2000) found no correlation across cancer sites between the 
long-run (40-year) change in the (conditional) survival rate and the unconditional 
mortality rate.
3  They concluded from this that “improving 5-year survival over 
time…should not be taken as evidence of improved prevention, screening, or therapy,” 
and “to avoid the problems introduced by changing patterns of diagnosis…progress 
against cancer [should] be assessed using population-based mortality rates.” 
  Bailar and Gornik (1997) assessed overall progress against
 cancer in the United 
States from 1970 through 1994 by analyzing
 changes in (unconditional) age-adjusted 
cancer mortality rates.  They concluded that “observed
 changes in mortality due to cancer 
primarily reflect changing
 incidence or early detection. The effect of new treatments for
 
cancer on mortality has been largely disappointing.”   
Bailar and Gornik’s assessment may have been unduly pessimistic: as shown in 
Figures 1b and 1c, during the period 1973-1994, the age-adjusted mortality rate increased 
6.4%, while the age-adjusted incidence rate increased 22.6%.  Although part of the 
relatively rapid growth of measured cancer incidence may have been due to improved 
detection, an important part may have been rapid growth in true incidence, due to a 
decline in competing mortality risks, especially from cardiovascular disease.  More 
people developed cancer because they had survived heart attacks. 
  In the early 1990s, there was a marked change in U.S. cancer mortality and 
incidence.  After rising steadily for 15 years, the age-adjusted mortality rate declined 
steadily, falling 17.2% between 1991 and 2006.  During the same period, the age-
adjusted incidence rate declined 9.7%. 
                                                 
3 However, Welch et al did not control for changes in cancer incidence.  Lichtenberg (2009) showed that, 
when incidence growth is controlled for, there is a highly significant correlation across cancer sites, in both 
the U.S. and Australia, between the change in 5-year survival for a specific tumor and the change in tumor-
related mortality.   3
  In this paper, I will analyze the effects of two important types of medical 
innovation—diagnostic imaging innovation and pharmaceutical innovation—and cancer 
incidence rates on unconditional cancer mortality rates since the early to mid 1990s.




The unconditional cancer mortality rate is essentially the unconditional 
probability of death from cancer (P(death from cancer)).  The law of total probability 
implies the following: 
 
P(death from cancer) = P(death from cancer | cancer diagnosis) * P(cancer diagnosis)  
 
+ P(death from cancer | no cancer diagnosis) * (1 – P( cancer diagnosis))       (1) 
 
If the probability that a person who has never been diagnosed with cancer dies from 
cancer is quite small (P(death from cancer | no cancer diagnosis) ≈ 0), which seems 
plausible, this reduces to  
 




ln P(death from cancer) ≈ ln P(death from cancer | cancer diagnosis)  
 
+ ln P(cancer diagnosis)        (3) 
 
I hypothesize that the conditional mortality rate (P(death from cancer | cancer diagnosis)) 
depends upon the average quality of imaging and pharmaceutical procedures:
5 
 
ln P(death from cancer | cancer diagnosis) = 1 image_quality + 2 drug_quality  (4) 
 
Substituting (4) into (3), 
 
ln P(death from cancer) ≈ 1 image_quality  
 
+ 2 drug_quality  + ln P(cancer diagnosis)     (5) 
                                                 
4 In previous studies (Lichtenberg 2008, 2009a, 2009b), I have examined the effect of pharmaceutical 
innovation on relative cancer survival rates, controlling for variables likely to reflect changes in probability 
of diagnosis (e.g. age at diagnosis, cancer stage of diagnosis, and number of people diagnosed). 
5 The average quality of imaging procedures may also affect the probability of diagnosis.   4
 
I will estimate difference-in-difference (DD) versions of eq. (5) using 
longitudinal, cancer-site-level data on over 60 cancer sites.
6  The equations will be of the 
following form: 
 
ln(mort_ratest) =  adv_imag%s,t-k +  new_drug%s,t-k  
 




mort_ratest  = the age-adjusted mortality rate from cancer at site s (s = 1,…, 60) in 
year t (t=1991,…,2006) 
adv_imag%s,t-k  = advanced imaging procedures as % of total imaging procedures 
associated with cancer at site s in year t-k (k=0,1,…) 
new_drug%s,t-k  = “new” (e.g. post-1990) drug procedures as % of all drug procedures 
associated with cancer at site s in year t-k (k=0,1,…) 
inc_rates,t-k  = the age-adjusted incidence rate of cancer at site s in year t-k 
s  = a fixed effect for cancer site s 
t  = a fixed effect for year t 
st = a disturbance 
 
If the replacement of standard imaging procedures by advanced imaging 
procedures has reduced the age-adjusted mortality rate, conditional on cancer drug 
innovation and cancer incidence, cancer sites that have had above-average increases in 
adv_imag% would have had above-average reductions in the age-adjusted mortality rate.  
This hypothesis may be tested by testing whether  < 0 in eq. (6).  Similarly, if the 
replacement of old drug procedures by new drug procedures has reduced the age-adjusted 
mortality rate, conditional on diagnostic imaging innovation and cancer incidence, cancer 
sites that have had above-average increases in new_drug% would have had above-
average reductions in the age-adjusted mortality rate.  This hypothesis may be tested by 
testing whether  < 0 in eq. (6).   
This equation will be estimated via weighted least-squares, weighting by the mean 
mortality rate of cancer site s during the entire sample period ((1 / T) ∑t mort_ratest).  The 
estimation procedure will account for clustering of disturbances within cancer sites.  Eq. 
                                                 
6 The cancer sites are those included in the National Cancer Institute’s  SEER Cause of Death Recode 
shown in Appendix Table 1.   5
(6) includes lagged values of adv_imag% and the other explanatory variables, since it 
may take several years for advanced imaging procedure utilization to have its peak effect 
on mortality rates. 
 The imaging procedure innovation measure will be constructed as follows: 
 
adv_imag%st   = p n_procpst advp  
        p n_procpst 
where 
 
n_procpst   = the number of times diagnostic imaging procedure p was performed in 
connection with cancer diagnosed at site s in year t 
advp   = 1 if procedure p is an advanced imaging procedure 
   = 0 if procedure p is a standard imaging procedure 
 
The drug procedure innovation measure will be constructed as follows: 
 
new_drug%st   = p n_procpst post_yearp  
          p n_procpst 
where 
 
n_procpst   = the number of times drug procedure p
7 was performed in connection with 
cancer diagnosed at site s in year t 
post_yearp   = 1 if the active ingredient of drug procedure p was approved by the FDA 
after year y
8 
   = 0 if the active ingredient of drug procedure p was approved by the FDA 
before year y+1 
 
 
                                                 
7 Drug procedures are procedures listed on MEDSTAT outpatient and inpatient claims with the following 
service types (STDSVC): chemotherapy (STDSVC=111), drugs (NEC) (STDSVC=155), or injectable 
medications (STDSVC=158). 
8 I will define y in two different ways: y=1990 and y=1995.   6
Data and descriptive statistics 
 
Cancer incidence and mortality rates.  Data on age-adjusted cancer incidence and 
mortality rates, by cancer site and year, were obtained from the National Cancer 
Institute’s Cancer Query Systems (http://seer.cancer.gov/canques/index.html).  Mortality 
data are based on a complete census of death certificates and are therefore not subject to 
sampling error, although they are subject to other errors, i.e. errors in reporting cause of 
death and age at death.
9  Cancer incidence rates are based on data collected from 
population-based cancer registries, which currently cover approximately 26 percent of the 
US population; incidence rates are therefore subject to sampling error. 
 
Diagnostic imaging innovation.  Data on the number of diagnostic imaging procedures, 
by CPT code
10, principal diagnosis (ICD9) code, and year (n_procpst) were obtained from 
MEDSTAT MarketScan Commercial Claims and Encounters Database produced by 
Thomson Medstat (Ann Arbor, MI).
11  Each claim in this database includes information 
about the procedure performed (CPT code), the patient’s diagnosis (ICD9 code), and the 
date of service.   
I used Berenson-Eggers Type of Service (BETOS) codes developed by CMS to 
determine whether each imaging procedure was a standard or advanced procedure (advp = 
0 or advp = 1).
12  The BETOS coding system was developed primarily for analyzing the 
growth in Medicare expenditures.  The coding system covers all HCPCS (including CPT) 
codes; assigns a HCPCS code to only one BETOS code; consists of readily understood 
                                                 
9 During the period 1979-1998, cause of death was coded using ICD9 codes.  Since 1999, cause of death 
has been coded using ICD10 codes.  An advantage of the National Cancer Institute’s Cancer Query 
Systems is that the mortality data from the two periods have been linked together.   
10 According to the American Medical Association’s CPT Assistant Archives, procedures with CPT codes 
between 70010 and 75893 are diagnostic imaging procedures.   
11 The MarketScan Databases capture person-specific clinical utilization, expenditures, and enrollment 
across inpatient, outpatient, prescription drug, and carve-out services from a selection of large employers, 
health plans, and government and public organizations. The MarketScan Databases link paid claims and 
encounter data to detailed patient information across sites and types of providers, and over time. The annual 
medical databases include private sector health data from approximately 100 payers. Historically, more 
than 500 million claim records are available in the MarketScan Databases. The Commercial Claims and 
Encounters Database provides data on the medical experience of active employees, early retirees, COBRA 
continues, and their dependents insured by employer-sponsored plans (i.e., non-Medicare eligibles).    
12 See the Centers for Medicare & Medicaid Services Berenson-Eggers Type of Service (BETOS) code 
database (http://www.cms.hhs.gov/HCPCSReleaseCodeSets/20_BETOS.asp#TopOfPage) 
   7
clinical categories (as opposed to statistical or financial categories); consists of categories 
that permit objective assignment; is stable over time; and is relatively immune to minor 
changes in technology or practice patterns.  Advanced imaging procedures (with a 
BETOS code beginning with I2) involve either a computed tomography (CT) scan or 
magnetic resonance imaging (MRI).  Standard imaging procedures have BETOS codes 
beginning with I1.  According to the 2006 BETOS Public Use File, 544 HCPCS codes 
correspond to standard imaging procedures, and 152 HCPCS codes correspond to 
advanced imaging procedures.  For example, code 71010 (Radiologic examination, chest; 
single view, frontal) is a standard imaging procedure, and code 70450 (Computed 
tomography, head or brain; without contrast material) is an advanced imaging procedure. 
The MEDSTAT Marketscan data are available during the period 1991-2007.  The 
coverage of the database expanded over time.  As shown in Figure 2, during the period 
1991-1995, the average annual number of imaging procedures associated with a cancer 
diagnosis was about 46,000.  During the period 1996-2001, the average annual number 
was about 90,000.  In 2007, the number of imaging procedures associated with a cancer 
diagnosis was about 771,000.   
Figure 2 also shows that the fraction of imaging procedures that were advanced 
procedures increased from 38% in 1991 to 70% in 2006.  Below we will show that the 
magnitude of the increase varied significantly across cancer sites.  Figure 3 illustrates the 
shift between 1991 and 2007 in the distribution of imaging procedures used on cancer 
patients: it shows the percent of 1991 and 2007 imaging procedures accounted for by the 
top 15 procedures in 2007.  The top two procedures in 2007 were CT scans.  They 
accounted for less than 6% of procedures in 1991, and over 20% of procedures in 2007. 
Although the MEDSTAT Marketscan database contains a large number of claims, 
it is not based on a nationally representative sample of Americans.  Moreover, the 
database I use contains data on medical care used by active employees, early retirees, 
COBRA continues, and their dependents insured by employer-sponsored plans.  Medical 
care used by people eligible for Medicare is not covered.
13  The majority of cancer 
patients are enrolled in Medicare.  Nevertheless, there is likely to be a strong positive 
                                                 
13 I do not have access to a separate MEDSTAT database that covers Medicare-eligible retirees with 
employer-sponsored Medicare Supplemental plans.   8
correlation across cancer sites between innovations in treatment of nonelderly and elderly 
patients.  If there was more treatment innovation for cancer type A than for cancer type B 
among nonelderly patients, there was likely to have been more treatment innovation for 
cancer type A than for cancer type B among elderly patients. 
 
Pharmaceutical innovation.  It is worth distinguishing between two types of drugs: self-
administered drugs, and drugs administered by physicians and other medical providers 
(e.g., chemotherapy).  Utilization of self-administered drugs is reported in outpatient 
prescription records (claims).  These records generally don’t include any information 
about the patient’s diagnosis.  In contrast, drugs that are administered by physicians and 
other medical providers are reported as outpatient and inpatient services (procedures).  
These records include information about the patient’s diagnosis.   
For most diseases other than cancer, most drug expenditure is on self-
administered drugs, and determining the diagnosis associated with a particular drug’s use 
(hence measuring n_procpst) can be difficult.  But the following table, based on 2007 
MEDSTAT data, shows that over two-thirds of cancer drug expenditure is on drugs 
administered by providers.   
  2007 payments (millions)   
Therapeutic Group 
provider-
administered self-administered  total 
provider-
administered 
as % of total 
Antineoplastic Agents  $1,179  $537  $1,717  69% 
Other drugs  $1,611  $14,958  $16,570  10% 
TOTAL $2,791  $15,495  $18,286  15% 
 
Data from IMS Health’s National Sales Perspectives are consistent with this: in 2004, 
clinics and hospitals accounted for 72% of U.S. expenditure on oncology drugs.  
Moreover some self-administered drugs contain the same active ingredients as provider-
administered drugs.  During the sample period (i.e. prior to Medicare Part D), a self-
administered drug was covered by Medicare only if there was a provider-administered 
drug with the same active ingredient.  We will use data on provider-administered drugs 
only, since the number of times provider-administered drug p was used to treat cancer 
originating at site s in year t can be measured precisely.     9
Data on the number of drug procedures, by HCPCS code, principal diagnosis 
(ICD9) code, and year, were also obtained from MEDSTAT MarketScan Commercial 
Claims and Encounters Database.  No drug procedure data are available for 1991, and as 
shown in Figure 4, during the period 1992-1998, the average annual number of drug 
procedures associated with a cancer diagnosis was about 10,000.  The number of drug 
procedures associated with a cancer diagnosis increased rapidly after 1998, from 83,000 
in 1999 to 2.2 million in 2007. 
Data on the active ingredient(s) contained in each drug procedure were obtained 
from Multum’s Lexicon database (http://www.multum.com/Lexicon.htm).  Data on the 
initial year of FDA approval of active ingredients were obtained from the Food and Drug 
Administration’s Drugs@FDA database 
(http://www.fda.gov/Drugs/InformationOnDrugs/ucm079750.htm).   
Due to delays in the establishment by CMS of procedure codes for new 
chemotherapy procedures, our measure of chemotherapy vintage (pharmaceutical 
innovation) is likely to be a “lagging indicator” of the true increase in chemotherapy 
treatment vintage.  The following table shows the FDA approval dates and HCPCS code 











daunorubicin liposomal  4/8/1996  1/1/1999  33 
docetaxel 5/14/1996  1/1/1998  20 
gemcitabine 5/15/1996  1/1/1998  20 
topotecan 5/28/1996  1/1/1998  19 
irinotecan 6/14/1996  1/1/1998  19 
FDA, Listing of Approved Oncology Drugs with Approved Indications, 
http://www.fda.gov/cder/cancer/druglistframe.htm 




HCPCS codes for these five drugs were established 19-33 months after FDA approval.  
These drugs were administered to patients prior to the establishment of their HCPCS 
codes.  The following table shows unpublished IMS Health data for four of these drugs   10
on the number of “standard units” sold in the U.S. via retail and hospital channels in the 
years 1996-1998. 
 1996  1997  1998 
docetaxel 36,962  115,191 211,728
gemcitabine 185,237 508,379 763,405
topotecan 88,987  150,492 170,665
irinotecan 117,510  371,832 439,420
 
According to one Medicare carrier, “J9999 [not otherwise classified, antineoplastic 
drugs] is the code that should be used for chemotherapy drugs that do not already have an 
assigned code.”
14  16% of chemotherapy treatments for patients with colorectal cancer 
used code J9999 in 2004.   
  Figure 4 shows that post-1990 drug procedures as a percent of total drug 
procedures increased from below 10% in 1992-1995 to over 36% in 2006-2007.  The 
mean fraction of total drug procedures that were post-1995 procedures increased from 
about 4% in 1992-1995 to 26% in 2006-2007.
15  Figure 5 illustrates the shift between 
1999 and 2007 in the distribution of drug procedures used on cancer patients: it shows the 
percent of 1999 and 2007 drug procedures accounted for by the top 15 procedures in 
2007.  The fifth most common procedure in 2007 (palonosetron) accounted for 3.8% of 
2007 drug procedures and 0.0% of 1999 drug procedures.  The FDA approved this drug 
in 2003.  The tenth most common procedure in 2007 (trastuzumab) accounted for 2.4% of 
2007 drug procedures and 0.0% of 1999 drug procedures.  The FDA approved this drug 
in 1998. 
  Table 1 shows statistics on mortality, incidence, diagnostic imaging procedures, 
and drug procedures, by cancer site in 1996 and 2006. 
 




15 One might expect the number of post-1995 procedures to be zero before 1996.  There may be a few 
errors in my procedure for determining the initial year of FDA approval of active ingredients.  Also, 
patients may have access to investigational drugs prior to their approval by the FDA.   11
Empirical results 
 
  Estimates of the model of the age-adjusted mortality rate (eq. (6)) are presented in 
Table 2.  Since the mortality rate may depend on lagged as well as contemporaneous 
values of incidence and innovation, there are many possible specifications (corresponding 
to different lag structures) of eq. (6).  To reduce the number of specifications, we will 
proceed as follows.  First, we will analyze the effect of just one variable—incidence in 
year t-k—on mortality in year t, for different values of k.  Next, we will analyze the effect 
of imaging innovation in year t-k on mortality in year t, for different values of k, 
conditional on the appropriate incidence lag and drug innovation in year t.  Finally, we 
will analyze the effect of drug innovation (measured in two different ways) in year t-k on 
mortality in year t, for different values of k, conditional on the appropriate incidence and 
imaging innovation lags. 
  Models 1 through 9 are fixed-effect regressions of mortality in year t on incidence 
in year t-k (k = 0,1,…,8).  The coefficients and 95% confidence limits from these models 
are plotted in Figure 6.  The coefficients of the first eight models are positive and 
significant at the 5% level.  The largest coefficient is for k = 5, suggesting that an 
increase in incidence has its largest impact on mortality with a five-year lag.   
The fact that changes in incidence have a significant effect on mortality suggests 
that at least part of the changes in incidence are “real”; changes in measured incidence 
are not purely a result of changes in measurement or screening.  Although the elasticity of 
mortality with respect to incidence is positive and significant, the largest estimate is 
substantially less than one: the coefficient on ln(inc_rates,t-5) in model 6 is .351.  This 
may be due to several factors: sampling error, changes in screening practices, and 
“learning by doing” or scale economies in cancer treatment: an increase in the number of 
patients with a given type of cancer may increase average treatment quality. 
Models 10 through 15 explore the imaging innovation lag structure: they are 
regressions of ln(mort_ratest) on adv_imag%s,t-k for different values of k (k= 0,1,…,5), 
controlling for new_drug%s,t and ln(inc_rates,t-5).  The imaging innovation coefficients 
and their 95% confidence limits are plotted (on an inverted scale) in Figure 7.  When k 
equals 0, 1, or 2, the imaging innovation coefficient is not statistically significant.  
However, when k equals 3, 4, or 5, the imaging innovation coefficient is negative and   12
significant.  This indicates that use of more advanced imaging procedures reduces cancer 
mortality rates 3-5 years later. 
Models 16 through 18 explore the drug innovation lag structure, using one 
measure of drug innovation: drug treatments involving ingredients approved by the FDA 
after 1990 as a fraction of total drug treatments (post1990%).  They are regressions of 
ln(mort_ratest) on post1990%s,t-k for different values of k (k= 0,1,2), controlling for 
adv_imag%s,t-5 and ln(inc_rates,t-5).  The coefficient on the contemporaneous drug 
innovation measure (post1990%s,t) in model 16 is negative and significant; the 
coefficients on lagged drug innovation in models 17 and 18 are not significant.  This may 
be due, in part, to the fact that post1990% is likely to be a “lagging indicator” of the true 
increase in chemotherapy treatment vintage, due to delays in the establishment by CMS 
of procedure codes for new chemotherapy procedures.  Also, the number of drug 
treatments early in the sample period was quite small. 
Models 19 through 21 explore the drug innovation lag structure, using an 
alternative measure of drug innovation: drug treatments involving ingredients approved 
by the FDA after 1995 as a fraction of total drug treatments (post1995%).  They are 
regressions of ln(mort_ratest) on post1995%s,t-k for different values of k (k= 0,1,2), 
controlling for adv_imag%s,t-5 and ln(inc_rates,t-5).  Once again, the coefficient on the 
contemporaneous drug innovation measure (post1995%s,t) in model 19 is negative and 
significant; the coefficients on lagged drug innovation in models 20 and 21 are not 
significant. 
Models 16 and 19 both indicate that there is a significant inverse relationship 
between the age-adjusted cancer mortality rate and both lagged imaging innovation and 
contemporaneous drug innovation, and a significant positive relationship between the 
age-adjusted cancer mortality rate and the lagged incidence rate.  While there is some 
correlation across cancer sites between changes in imaging innovation, drug innovation, 
and incidence, Table 3 shows that we obtain similar estimates of the effects of imaging 
and drug innovation on the cancer mortality rate, whether or not we control for the other 
factors. 
During the sample period (1996-2006), the age-adjusted cancer mortality rate 
declined 13.4%, from 207.0 to 181.1 deaths per 100,000 population.  We can use our   13
estimates to assess the contributions of imaging innovation, drug innovation, and 
declining cancer incidence to this decline in the cancer mortality rate.  For example, the 
estimated contribution of imaging innovation is  (adv_imag%.,1991 - adv_imag%.,2001), 
where adv_imag%.,t is the (weighted) average value of adv_imag% across all cancer sites 
in year t.  Using the estimates of , , and  from model 16 in Table 2, we obtain the 
following decomposition of the 1996-2006 decline in cancer mortality: 
Factor   Contribution to the 1996-2006 decline in 
the age-adjusted cancer mortality rate 
imaging innovation  5.3% 
drug innovation  3.7% 
decline in age-adjusted incidence  1.0% 
other factors  3.4% 
TOTAL 13.4% 
 
Imaging innovation, drug innovation, and declining incidence jointly explain about three-
fourths of the decline in cancer mortality.  Only 7% of the mortality decline is attributable 
to the decline in (lagged) incidence.  About one-fourth (27%) of the mortality decline is 
attributable to drug innovation, and 40% of the decline is attributable to (lagged) imaging 
innovation. 
  If we assume that the decline in cancer mortality had no effect on (did not 
increase) mortality from other causes of death, we can also estimate how much cancer 
imaging and drug innovation increased life expectancy at birth in the U.S. between 1996 
and 2006.  The calculations above imply that cancer imaging innovation and drug 
innovation reduced the cancer mortality rate by 10.2 (= 40% * 25.9) and 7.1 (= 27% * 
25.9) deaths per 100,000 population, respectively.  During this period, the age-adjusted 
mortality rate from all causes of death declined by 119.4 deaths per 100,000 population, 
from 894.5 to 775.1, and life expectancy at birth increased by 1.6 years, from 76.1 to 77.7 
years.
16  If the decline in cancer mortality had no effect on mortality from other causes of 
death, about 9% (= 10.2 / 119.4) of the decline in the mortality rate from all causes of 
death is attributable to cancer imaging innovation, and about 6% is attributable to cancer 
drug innovation.  Life expectancy at birth may have been increased by just under three 
                                                 
16 Life expectancy at birth and the age-adjusted mortality rate from all causes of death are both calculated 
from age-specific rates of mortality from all causes of death.   14
months (= (9% + 6%) * 1.6 years) between 1996 and 2006 by the combined effects of 
cancer imaging and cancer drug innovation.  Research by Nordhaus (2003), Viscusi 
(2004), and Murphy and Topel (2006) indicates that Americans place a high value on 




Several previous studies have examined the overall impact of medical innovation 
on cancer mortality.  These studies may have been subject to several limitations.  First, 
the outcome measure in all of these studies was the cancer survival rate—the proportion 
of patients alive at some point subsequent to the diagnosis of their cancer—and this 
measure may be subject to lead-time bias.  Second, only one kind of medical 
innovation—chemotherapy innovation—was usually analyzed, and this was usually 
measured by the number of drugs potentially available to cancer patients, rather than by 
the drugs actually used by them. 
This paper builds upon previous research in several ways.  First, the outcome 
measure we use—the unconditional cancer mortality rate (the number of deaths, with 
cancer as the underlying cause of death, occurring during a year per 100,000 
population)—is not subject to lead-time bias.  Second, we analyze the effects of two 
important types of medical innovation—diagnostic imaging innovation and 
pharmaceutical innovation—and cancer incidence rates on cancer mortality rates.  Third, 
our measures of medical innovation are based on extensive data on treatments given to 
large numbers of patients with different types of cancer. 
We estimated difference-in-difference models of the age-adjusted cancer 
mortality rate using longitudinal, annual, cancer-site-level data on over 60 cancer sites 
during the period 1996-2006.  There was a significant inverse relationship between the 
cancer mortality rate and both lagged imaging innovation and contemporaneous drug 
innovation, and a significant positive relationship between the cancer mortality rate and 
the lagged incidence rate.  Imaging innovation, drug innovation, and declining incidence 
jointly explain about three-fourths of the decline in cancer mortality.  Only 7% of the 
mortality decline is attributable to the decline in (lagged) incidence.  About one-fourth   15
(27%) of the mortality decline is attributable to drug innovation, and 40% of the decline 
is attributable to (lagged) imaging innovation.  Our findings do not support the 
conclusions of a 1997 article assessing progress in the war on cancer: “observed
 changes 
in mortality due to cancer primarily reflect changing
 incidence or early detection.  The 
effect of new treatments for
 cancer on mortality has been largely disappointing.”  Our 
findings also imply that the statement by Black and Welch (1993) that “the increasing use 
of sophisticated diagnostic imaging promotes a cycle of increasing intervention that often 
confers little or no benefit” does not apply to cancer. 
If the decline in cancer mortality had no effect on mortality from other causes of 
death, about 9% of the decline in the mortality rate from all causes of death is attributable 
to cancer imaging innovation, and about 6% is attributable to cancer drug innovation.  
Life expectancy at birth may have been increased by just under three months between 
1996 and 2006 by the combined effects of cancer imaging and cancer drug innovation.   
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advanced procedures as % of total procedures (left axis)
Number of MEDSTAT imaging procedures  associated with cancer diagnosis (right axis)Figure 3
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post-1990 drug procedures as % of total drug procedures (left axis)
post-1995 drug procedures as % of total drug procedures (left axis)
Number of MEDSTAT drug procedures associated with cancer diagnosis (right axis)Figure 5
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95% Lower Confidence Limit
Estimate
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95% Lower Confidence Limit
Estimate
95% Upper Confidence Limit
Note: values are plotted on an inverted scaleRecode Site 1996 2006 1996 2006 1,996 2,006 1996 2006 1,996 2,006 1996 2006 1996 2006
20010 Lip 0.0 0.0 1.3 0.7 10 73 20% 70% . 34 . 18% . 15%
20020 Tongue 0.7 0.6 2.6 2.9 307 1,926 40% 74% 35 7,885 0% 34% 0% 15%
20030 Salivary Gland 0.2 0.2 1.3 1.3 205 649 78% 81% . 881 . 36% . 21%
20040 Floor of Mouth 0.1 0.0 1.1 0.5 37 154 22% 68% . 189 . 49% . 12%
20050 Gum and Other Mouth 0.5 0.4 1.8 1.6 169 582 44% 65% 5 455 0% 35% 0% 17%
20060 Nasopharynx 0.3 0.2 0.8 0.6 138 731 54% 79% 41 3,138 15% 25% 0% 10%
20070 Tonsil 0.2 0.2 1.2 1.5 117 1,410 41% 77% . 4,013 . 31% . 16%
20080 Oropharynx 0.2 0.2 0.3 0.3 32 423 50% 80% 1 1,142 0% 30% 0% 15%
20090 Hypopharynx 0.2 0.1 0.9 0.6 35 175 49% 70% . 1,012 . 37% . 22%
20100 Other Oral Cavity and Pharynx 0.6 0.5 0.4 0.2 81 358 46% 73% 11 627 0% 38% 0% 13%
21010 Esophagus 4.3 4.4 4.8 4.6 1,082 5,336 34% 69% 66 17,599 6% 28% 0% 19%
21020 Stomach 5.1 3.7 8.5 7.3 648 3,089 46% 79% 151 12,184 7% 27% 7% 20%
21030 Small Intestine 0.4 0.4 1.7 2.0 128 766 45% 83% 19 2,754 0% 29% 0% 25%
21040 Colon excluding Rectum 18.7 14.3 39.3 32.9 3,296 22,609 51% 84% 1,635 163,182 2% 31% 0% 27%
21050 Rectum and Rectosigmoid Junction 3.1 2.8 15.4 12.5 2,003 10,749 56% 83% 1,124 64,513 1% 31% 0% 25%
21060 Anus, Anal Canal and Anorectum 0.2 0.2 1.3 1.4 111 1,243 55% 86% 38 4,833 0% 28% 0% 21%
21071 Liver 3.6 4.1 4.6 6.1 370 1,927 61% 79% 11 2,160 0% 28% 0% 21%
21072 Intrahepatic Bile Duct 0.9 1.2 0.9 0.6 196 1,085 84% 85% . 1,167 . 42% . 36%
21080 Gallbladder 0.8 0.6 1.1 1.1 90 437 54% 82% 34 1,911 0% 40% 0% 31%
21090 Other Biliary 0.6 0.5 1.3 1.7 81 503 31% 72% . 1,382 . 38% . 30%
21100 Pancreas 10.5 10.8 11.3 12.0 1,033 6,621 58% 83% 108 22,778 0% 44% 0% 36%
21110 Retroperitoneum 0.1 0.1 0.4 0.4 88 488 86% 87% . 344 . 36% . 26%
21120 Peritoneum, Omentum and Mesentery 0.2 0.3 0.5 0.7 72 525 65% 76% 60 1,135 12% 35% 0% 22%
21130 Other Digestive Organs 0.2 0.3 0.4 0.6 78 226 50% 92% . 173 . 34% . 23%
22010 Nose, Nasal Cavity and Middle Ear 0.2 0.1 0.7 0.6 253 509 69% 86% . 800 . 33% . 26%
22020 Larynx 1.5 1.2 4.3 3.2 349 1,555 39% 73% 30 4,120 0% 35% 0% 18%
22030 Lung and Bronchus 57.9 51.7 66.4 60.0 10,425 39,897 39% 70% 2,301 142,887 26% 40% 9% 27%
22050 Pleura 0.2 0.1 0.0 0.0 51 122 39% 57% 1 385 0% 35% 0% 27%
22060 Trachea, Mediastinum and Other Respiratory Organs 0.1 0.1 0.2 0.2 769 350 40% 76% 66 1,103 14% 27% 0% 16%
23000 Bones and Joints 0.5 0.4 0.8 0.9 912 2,572 54% 47% 3 1,767 0% 29% 0% 14%
24000 Soft Tissue including Heart 1.5 1.3 2.8 3.0 1,502 7,304 53% 74% 85 10,183 20% 34% 20% 21%
25010 Melanoma of the Skin 2.8 2.7 17.3 21.1 2,267 10,823 38% 60% 333 13,647 8% 17% 1% 6%







Mortality, incidence, diagnostic imaging procedures, and drug procedures, by cancer site in 1996 and 2006
mortality rate incidence rate
no. of imaging 
procs.
advanced 
imaging %Recode Site 1996 2006 1996 2006 1,996 2,006 1996 2006 1,996 2,006 1996 2006 1996 2006
25020 Other Non-Epithelial Skin 0.8 0.8 1.9 1.7 339 1,153 23% 64% 39 3,033 3% 19% 3% 10%
26000 Breast 16.8 13.2 73.2 66.4 27,894 93,405 16% 48% 3,836 361,396 13% 43% 3% 32%
27010 Cervix Uteri 1.6 1.2 4.8 3.4 651 3,018 44% 79% 15 9,870 0% 26% 0% 15%
27020 Corpus Uteri 1.1 1.0 12.2 11.8 558 4,635 47% 79% 27 9,232 22% 32% 7% 18%
27030 Uterus, NOS 1.0 1.1 0.3 0.3 270 1,577 55% 84% 8 1,410 0% 38% 0% 23%
27040 Ovary 4.5 4.3 7.1 6.3 1,915 10,863 59% 85% 566 50,287 30% 37% 0% 23%
27050 Vagina 0.2 0.1 0.3 0.4 53 267 45% 86% . 625 . 39% . 35%
27060 Vulva 0.2 0.3 1.2 1.2 95 397 41% 67% . 1,821 . 22% . 10%
27070 Other Female Genital Organs 0.1 0.1 0.4 0.4 181 281 54% 81% 26 897 8% 28% 0% 14%
28010 Prostate 18.0 11.8 84.5 81.6 3,132 17,389 46% 74% 636 17,728 3% 35% 1% 26%
28020 Testis 0.2 0.1 2.7 2.8 1,125 8,923 54% 74% 96 10,754 23% 22% 23% 13%
28030 Penis 0.1 0.1 0.3 0.3 25 131 60% 88% . 49 . 55% . 51%
28040 Other Male Genital Organs 0.0 0.0 0.2 0.2 78 151 72% 79% . 36 . 0% . 0%
29010 Urinary Bladder 4.4 4.3 20.8 20.5 1,256 6,148 34% 63% 291 16,316 4% 23% 1% 17%
29020 Kidney and Renal Pelvis 4.3 4.0 11.4 13.9 1,766 14,392 50% 77% 441 4,309 18% 41% 1% 29%
29030 Ureter 0.1 0.1 0.6 0.7 94 197 26% 52% 1 312 0% 36% 0% 26%
29040 Other Urinary Organs 0.1 0.1 0.3 0.3 150 319 59% 81% 5 359 0% 35% 0% 27%
30000 Eye and Orbit 0.1 0.1 0.9 0.8 244 599 73% 76% . 379 . 22% . 8%
31010 Brain and Other Nervous System 4.7 4.2 6.6 6.1 4,225 10,766 90% 93% 73 6,624 15% 38% 0% 27%
32010 Thyroid 0.5 0.5 6.5 11.0 463 3,117 36% 63% . 2,935 . 58% . 51%
32020 Other Endocrine including Thymus 0.3 0.3 0.7 0.8 545 2,309 69% 86% . 3,189 . 28% . 17%
33010 Hodgkin Lymphoma 0.5 0.4 2.8 2.9 2,517 9,188 60% 82% 443 20,361 7% 20% 5% 14%
33040 Non-Hodgkin Lymphoma 8.8 6.7 19.4 19.5 7,807 38,616 69% 89% 1,376 84,503 28% 33% 5% 24%
34000 Myeloma 3.9 3.5 5.8 5.4 1,324 6,661 32% 49% 166 26,099 6% 55% 2% 39%
35011 Acute Lymphocytic Leukemia 0.5 0.5 1.4 1.4 192 1,373 24% 43% 117 7,641 0% 17% 0% 5%
35012 Chronic Lymphocytic Leukemia 1.7 1.4 4.6 4.3 228 2,278 39% 82% 73 16,319 59% 46% 0% 25%
35013 Other Lymphocytic Leukemia 0.2 0.1 0.5 0.3 80 241 50% 81% 1 906 0% 39% 0% 18%
35022 Chronic Myeloid Leukemia 0.9 0.3 1.8 1.5 205 375 17% 45% 71 1,069 4% 38% 0% 31%
35023 Other Myeloid/Monocytic Leukemia 0.1 0.2 0.2 0.1 36 124 11% 68% 18 381 0% 29% 0% 25%
35031 Acute Monocytic Leukemia 0.1 0.0 0.2 0.2 26 48 8% 33% . 110 . 23% . 8%
35041 Other Acute Leukemia 1.0 0.7 0.5 0.2 253 841 38% 54% 11 6,979 0% 51% 0% 43%
37000 Miscellaneous Malignant Cancer 14.4 13.7 . . 5,435 11,020 64% 75% 304 20,906 13% 35% 3% 21%
Table 1 (continued)
Mortality, incidence, diagnostic imaging procedures, and drug procedures, by cancer site in 1996 and 2006
mortality rate incidence rate

















Z Pr > |Z|
1 ln(inc_rates,t)  0.293 0.100 0.098 0.488 2.95 0.0032
2 ln(inc_rates,t-1)  0.276 0.104 0.071 0.481 2.64 0.0082
3 ln(inc_rates,t-2)  0.231 0.108 0.020 0.442 2.15 0.0319
4 ln(inc_rates,t-3)  0.263 0.090 0.086 0.440 2.91 0.0036
5 ln(inc_rates,t-4)  0.296 0.072 0.154 0.438 4.09 <.0001
6 ln(inc_rates,t-5)  0.351 0.072 0.211 0.491 4.91 <.0001
7 ln(inc_rates,t-6)  0.313 0.060 0.196 0.429 5.25 <.0001
8 ln(inc_rates,t-7)  0.198 0.078 0.044 0.351 2.52 0.0118
9 ln(inc_rates,t-8)  0.124 0.103 -0.078 0.325 1.20 0.2298
10 adv_imag%s,t -0.031 0.142 -0.309 0.248 -0.22 0.829
10 post1990%s,t -0.152 0.072 -0.292 -0.011 -2.11 0.0348
10 ln(inc_rates,t-5)  0.321 0.070 0.183 0.459 4.56 <.0001
11 adv_imag%s,t-1 -0.110 0.106 -0.317 0.097 -1.04 0.2979
11 post1990%s,t -0.155 0.072 -0.295 -0.015 -2.16 0.0305
11 ln(inc_rates,t-5)  0.313 0.070 0.176 0.450 4.49 <.0001
12 adv_imag%s,t-2 -0.128 0.096 -0.316 0.060 -1.34 0.1806
12 post1990%s,t -0.150 0.071 -0.289 -0.011 -2.11 0.0345
12 ln(inc_rates,t-5)  0.308 0.071 0.170 0.447 4.36 <.0001
13 adv_imag%s,t-3 -0.252 0.070 -0.390 -0.113 -3.57 0.0004
13 post1990%s,t -0.159 0.068 -0.293 -0.025 -2.33 0.0198
13 ln(inc_rates,t-5)  0.299 0.068 0.165 0.433 4.37 <.0001
Incidence lag structure
Advanced imaging lag structure
Note: The dependent variable is ln(mort_ratest).  The equations were estimated via weighted least-squares, 
weighting by the mean mortality rate of cancer site s during the entire sample period ((1 / T) ∑t mort_ratest). 
The estimation procedure accounts for clustering of disturbances within cancer sites.  
Table 2
Estimates of eq. (6)Model







Z Pr > |Z|
14 adv_imag%s,t-4 -0.224 0.080 -0.382 -0.067 -2.79 0.0052
14 post1990%s,t -0.157 0.069 -0.291 -0.022 -2.29 0.0222
14 ln(inc_rates,t-5)  0.294 0.074 0.149 0.439 3.98 <.0001
15 adv_imag%s,t-5 -0.252 0.079 -0.407 -0.097 -3.18 0.0015
15 post1990%s,t -0.161 0.066 -0.290 -0.032 -2.44 0.0145
15 ln(inc_rates,t-5)  0.296 0.071 0.156 0.436 4.14 <.0001
16 adv_imag%s,t-5 -0.252 0.079 -0.407 -0.097 -3.18 0.0015
16 post1990%s,t -0.161 0.066 -0.290 -0.032 -2.44 0.0145
16 ln(inc_rates,t-5)  0.296 0.071 0.156 0.436 4.14 <.0001
17 adv_imag%s,t-5 -0.231 0.089 -0.404 -0.057 -2.61 0.0091
17 post1990%s,t-1 -0.107 0.065 -0.234 0.019 -1.66 0.0962
17 ln(inc_rates,t-5)  0.318 0.085 0.152 0.485 3.75 0.0002
18 adv_imag%s,t-5 -0.231 0.086 -0.399 -0.062 -2.68 0.0074
18 post1990%s,t-2 -0.055 0.049 -0.150 0.040 -1.14 0.2562
18 ln(inc_rates,t-5)  0.328 0.085 0.161 0.495 3.84 0.0001
19 adv_imag%s,t-5 -0.229 0.085 -0.397 -0.062 -2.69 0.0072
19 post1995%s,t -0.161 0.074 -0.305 -0.016 -2.18 0.0294
19 ln(inc_rates,t-5)  0.307 0.076 0.158 0.455 4.04 <.0001
20 adv_imag%s,t-5 -0.215 0.095 -0.401 -0.030 -2.28 0.0228
20 post1995%s,t-1 -0.083 0.087 -0.253 0.088 -0.95 0.3433
20 ln(inc_rates,t-5)  0.319 0.085 0.152 0.487 3.75 0.0002
21 adv_imag%s,t-5 -0.221 0.088 -0.394 -0.048 -2.51 0.0122
21 post1995%s,t-2 -0.037 0.070 -0.173 0.100 -0.52 0.6003
21 ln(inc_rates,t-5) 0.328 0.085 0.163 0.494 3.88 0.0001
Post-1990 drug lag structure
Post-1995 drug lag structure
Table 2 (continued)
Estimates of eq. (6)










Z Pr > |Z|
adv_imag%s,t-5 post1990%s,t, ln(inc_rates,t-5)  -0.252 0.079 -0.407 -0.097 -3.18 0.0015
adv_imag%s,t-5 none -0.286 0.098 -0.478 -0.093 -2.90 0.0037
post1990%s,t adv_imag%s,t, ln(inc_rates,t-5)  -0.161 0.066 -0.290 -0.032 -2.44 0.0145
post1990%s,t none -0.164 0.073 -0.306 -0.022 -2.26 0.0239
post1995%s,t adv_imag%s,t, ln(inc_rates,t-5)  -0.161 0.074 -0.305 -0.016 -2.18 0.0294
post1995%s,t none -0.205 0.089 -0.380 -0.030 -2.30 0.0216
Table 3
Estimates of effects of imaging and drug innovation on cancer mortality rate, controlling and not controlling for 
other factorsCancer Causes of Death ICD-9 Recode
All Malignant Cancers 140-208, 238.6 --
Oral Cavity and Pharynx
    Lip 140 20010
    Tongue 141 20020
    Salivary Gland 142 20030
    Floor of Mouth 144 20040
    Gum and Other Mouth 143, 145 20050
    Nasopharynx 147 20060
    Tonsil 146.0-146.2 20070
    Oropharynx 146.3-146.9 20080
    Hypopharynx 148 20090
    Other Oral Cavity and Pharynx 149 20100
Digestive System
    Esophagus 150 21010
    Stomach 151 21020
    Small Intestine 152 21030
    Colon and Rectum
        Colon excluding Rectum 153, 159.0 21040
        Rectum and Rectosigmoid Junction 154.0-154.1 21050
    Anus, Anal Canal and Anorectum 154.2-154.3, 154.8 21060
    Liver and Intrahepatic Bile Duct
        Liver 155.0, 155.2 21071
        Intrahepatic Bile Duct 155.1 21072
    Gallbladder 156.0 21080
    Other Biliary 156.1-156.2, 156.8-156.9 21090
    Pancreas 157 21100
    Retroperitoneum 158.0 21110
    Peritoneum, Omentum and Mesentery 158.8-158.9 21120
    Other Digestive Organs 159.8-159.9 21130
Respiratory System
    Nose, Nasal Cavity and Middle Ear 160 22010
    Larynx 161 22020
    Lung and Bronchus 162.2-162.5, 162.8-162.9 22030
    Pleura 163 22050
    Trachea, Mediastinum and Other Respiratory Organs
162.0, 164.2-164.3, 164.8-
164.9, 165 22060
Bones and Joints 170 23000
Soft Tissue including Heart$ 164.1, 171 24000
Skin excluding Basal and Squamous
    Melanoma of the Skin 172 25010
    Other Non-Epithelial Skin 173 25020
Breast 174-175 26000
Female Genital System
    Cervix Uteri 180 27010
    Corpus and Uterus, NOS
        Corpus Uteri 182 27020
        Uterus, NOS 179 27030
    Ovary 183.0 27040
Appendix Table 1
SEER Cause of Death Recode 1969+ (9/17/2004) Cancer Causes of Death ICD-9 (1979-1998) Recode
    Vagina 184.0 27050
    Vulva 184.1-184.4 27060
    Other Female Genital Organs
181, 183.2-183.5, 183.8-183.9, 
184.8-184.9 27070
Male Genital System
    Prostate 185 28010
    Testis 186 28020
    Penis 187.1-187.4 28030
    Other Male Genital Organs 187.5-187.9 28040
Urinary System
    Urinary Bladder 188 29010
    Kidney and Renal Pelvis 189.0-189.1 29020
    Ureter 189.2 29030
    Other Urinary Organs 189.3-189.4, 189.8-189.9 29040
Eye and Orbit 190 30000
Brain and Other Nervous System 191, 192 31010
Endocrine System
    Thyroid 193 32010
    Other Endocrine including Thymus$ 164.0, 194 32020
Lymphoma
    Hodgkin Lymphoma 201 33010
    Non-Hodgkin Lymphoma 200, 202.0-202.2, 202.8-202.9 33040
Myeloma 203.0, 238.6 34000
Leukemia
    Lymphocytic Leukemia
        Acute Lymphocytic Leukemia 204.0 35011
        Chronic Lymphocytic Leukemia 204.1 35012
        Other Lymphocytic Leukemia 202.4, 204.2, 204.8-204.9 35013
    Myeloid and Monocytic Leukemia
        Acute myeloid 205.0, 207.0, 207.2 35021
        Acute Monocytic Leukemia 206.0 35031
        Chronic Myeloid Leukemia 205.1 35022
        Other Myeloid/Monocytic Leukemia
205.2-205.3, 205.8-205.9, 
206.1-206.2, 206.8-206.9 35023
    Other Leukemia
        Other Acute Leukemia 208.0 35041
        Aleukemic, subleukemic and NOS
203.1, 207.1, 207.8, 208.1-
208.2, 208.8-208.9 35043
Mesothelioma (ICD-10 only)+ N/A 36010
Kaposi Sarcoma (ICD-10 only)+ N/A 36020
Miscellaneous Malignant Cancer
159.1, 195-199, 202.3, 202.5-
202.6, 203.8 37000
Appendix Table 1 (continued)
SEER Cause of Death Recode 1969+ (9/17/2004) 